NP / PA
Randazzo, Tiffany
Randazzo, Tiffany was paid $834K by Medicaid between Apr 2019 and Nov 2024, across 61 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 15% of everything it billed.
33Billing provider infoRANDAZZO, TIFFANY
MANHASSET, NY 11030
MANHASSET, NY 11030
33aNPI1144738543assigned 01/19/2018
33bProvider typeGerontology Nurse Practitioner
28Total paid$834K
24GClaims32,373
24DCodes billed61
24AFirst – last monthApr 2019 – Nov 2024
Compared with peers
Next to other Gerontology Nurse Practitioner providers in New York
Rank by total paid#3 of 52
Median peer was paid$2K
This provider vs. median345×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 561 | $3K | |
| 2020 | 7,856 | $219K | |
| 2021 | 8,874 | $224K | |
| 2022 | 6,422 | $178K | |
| 2023 | 5,799 | $141K | |
| 2024incomplete | 2,861 | $69K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 2,034 | 1,892 | $123K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 15% | 836 | 777 | $121K |
| 51728 | 9.1% | 701 | 694 | $76K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.0% | 1,954 | 1,796 | $75K |
| 99442 | 9.0% | 2,235 | 2,175 | $75K | |
| 51784 | 6.0% | 1,187 | 1,074 | $50K | |
| 51792 | 5.7% | 278 | 277 | $47K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.4% | 430 | 423 | $45K |
| 76857 | 3.8% | 1,062 | 1,048 | $32K | |
| 51741 | 2.9% | 2,604 | 2,162 | $24K | |
| 51798 | 1.6% | 1,744 | 1,708 | $13K | |
| 93976 | 1.6% | 127 | 127 | $13K |
49 more codes
| 87640 | 1.5% | 831 | $13K | |
| 87556 | 1.5% | 774 | $13K | |
| 87653 | 1.2% | 812 | $10K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 774 | $9K |
| 87563 | 1.1% | 341 | $9K | |
| 76872 | 1.0% | 108 | $9K | |
| 87481 | <1% | 695 | $7K | |
| 87081 | <1% | 3,141 | $7K | |
| 99401 | <1% | 269 | $7K | |
| 88112 | <1% | 194 | $6K | |
| 88313 | <1% | 194 | $6K | |
| 81003 | <1% | 4,360 | $4K | |
| 51729 | <1% | 14 | $3K | |
| 99072 | <1% | 225 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 36 | $3K |
| 52000 | <1% | 24 | $3K | |
| 84153 | <1% | 436 | $3K | |
| 84403 | <1% | 208 | $2K | |
| 51797 | <1% | 14 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 456 | $2K |
| 87150 | <1% | 13 | $1K | |
| 87529 | <1% | 68 | $1K | |
| 87532 | <1% | 100 | $1K | |
| 83001 | <1% | 182 | $1K | |
| 83002 | <1% | 170 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 21 | $1K |
| 93980 | <1% | 12 | $904.93 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 284 | $806.83 |
| 87496 | <1% | 41 | $759.60 | |
| 76870 | <1% | 13 | $744.34 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 39 | $715.40 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 39 | $660.73 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17 | $641.54 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $598.53 |
| 87511 | <1% | 55 | $574.42 | |
| 76775 | <1% | 108 | $566.88 | |
| 84146 | <1% | 89 | $566.31 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,371 | $528.27 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 28 | $496.78 |
| 87498 | <1% | 38 | $493.26 | |
| 87486 | <1% | 38 | $493.26 | |
| 87581 | <1% | 38 | $493.26 | |
| 87541 | <1% | 37 | $438.50 | |
| 87500 | <1% | 29 | $418.09 | |
| 81002 | <1% | 281 | $405.02 | |
| 54235 | <1% | 12 | $354.40 | |
| 87186 | <1% | 61 | $140.16 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 45 | $20.64 |
| 87088 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.